Cargando…

The CNDP1 (CTG)(5) Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration

Considering that the homozygous CNDP1 (CTG)(5) genotype affords protection against diabetic nephropathy (DN) in female patients with type 2 diabetes, this study assessed if this association remains gender-specific when applying clinical inclusion criteria (CIC-DN) or biopsy proof (BP-DN). Additional...

Descripción completa

Detalles Bibliográficos
Autores principales: Albrecht, Thomas, Zhang, Shiqi, Braun, Jana D., Xia, Li, Rodriquez, Angelica, Qiu, Jiedong, Peters, Verena, Schmitt, Claus P., van den Born, Jacob, Bakker, Stephan J. L., Lammert, Alexander, Köppel, Hannes, Schnuelle, Peter, Krämer, Bernhard K., Yard, Benito A., Hauske, Sibylle J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434468/
https://www.ncbi.nlm.nih.gov/pubmed/28553654
http://dx.doi.org/10.1155/2017/9506730
_version_ 1783237054314840064
author Albrecht, Thomas
Zhang, Shiqi
Braun, Jana D.
Xia, Li
Rodriquez, Angelica
Qiu, Jiedong
Peters, Verena
Schmitt, Claus P.
van den Born, Jacob
Bakker, Stephan J. L.
Lammert, Alexander
Köppel, Hannes
Schnuelle, Peter
Krämer, Bernhard K.
Yard, Benito A.
Hauske, Sibylle J.
author_facet Albrecht, Thomas
Zhang, Shiqi
Braun, Jana D.
Xia, Li
Rodriquez, Angelica
Qiu, Jiedong
Peters, Verena
Schmitt, Claus P.
van den Born, Jacob
Bakker, Stephan J. L.
Lammert, Alexander
Köppel, Hannes
Schnuelle, Peter
Krämer, Bernhard K.
Yard, Benito A.
Hauske, Sibylle J.
author_sort Albrecht, Thomas
collection PubMed
description Considering that the homozygous CNDP1 (CTG)(5) genotype affords protection against diabetic nephropathy (DN) in female patients with type 2 diabetes, this study assessed if this association remains gender-specific when applying clinical inclusion criteria (CIC-DN) or biopsy proof (BP-DN). Additionally, it assessed if the prevalence of the protective genotype changes with diabetes duration and time on hemodialysis and if this occurs in association with serum carnosinase (CN-1) activity. Whereas the distribution of the (CTG)(5) homozygous genotype in the no-DN and CIC-DN patients was comparable, a lower frequency was found in the BP-DN patients, particularly in females. We observed a significant trend towards high frequencies of the (CTG)(5) homozygous genotype with increased time on dialysis. This was also observed for diabetes duration but only reached significance when both (CTG)(5) homo- and heterozygous patients were included. CN-1 activity negatively correlated with time on hemodialysis and was lower in (CTG)(5) homozygous patients. The latter remained significant in female subjects after gender stratification. We confirm the association between the CNDP1 genotype and DN to be likely gender-specific. Although our data also suggest that (CTG)(5) homozygous patients may have a survival advantage on dialysis and in diabetes, this hypothesis needs to be confirmed in a prospective cohort study.
format Online
Article
Text
id pubmed-5434468
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-54344682017-05-28 The CNDP1 (CTG)(5) Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration Albrecht, Thomas Zhang, Shiqi Braun, Jana D. Xia, Li Rodriquez, Angelica Qiu, Jiedong Peters, Verena Schmitt, Claus P. van den Born, Jacob Bakker, Stephan J. L. Lammert, Alexander Köppel, Hannes Schnuelle, Peter Krämer, Bernhard K. Yard, Benito A. Hauske, Sibylle J. J Diabetes Res Research Article Considering that the homozygous CNDP1 (CTG)(5) genotype affords protection against diabetic nephropathy (DN) in female patients with type 2 diabetes, this study assessed if this association remains gender-specific when applying clinical inclusion criteria (CIC-DN) or biopsy proof (BP-DN). Additionally, it assessed if the prevalence of the protective genotype changes with diabetes duration and time on hemodialysis and if this occurs in association with serum carnosinase (CN-1) activity. Whereas the distribution of the (CTG)(5) homozygous genotype in the no-DN and CIC-DN patients was comparable, a lower frequency was found in the BP-DN patients, particularly in females. We observed a significant trend towards high frequencies of the (CTG)(5) homozygous genotype with increased time on dialysis. This was also observed for diabetes duration but only reached significance when both (CTG)(5) homo- and heterozygous patients were included. CN-1 activity negatively correlated with time on hemodialysis and was lower in (CTG)(5) homozygous patients. The latter remained significant in female subjects after gender stratification. We confirm the association between the CNDP1 genotype and DN to be likely gender-specific. Although our data also suggest that (CTG)(5) homozygous patients may have a survival advantage on dialysis and in diabetes, this hypothesis needs to be confirmed in a prospective cohort study. Hindawi 2017 2017-05-03 /pmc/articles/PMC5434468/ /pubmed/28553654 http://dx.doi.org/10.1155/2017/9506730 Text en Copyright © 2017 Thomas Albrecht et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Albrecht, Thomas
Zhang, Shiqi
Braun, Jana D.
Xia, Li
Rodriquez, Angelica
Qiu, Jiedong
Peters, Verena
Schmitt, Claus P.
van den Born, Jacob
Bakker, Stephan J. L.
Lammert, Alexander
Köppel, Hannes
Schnuelle, Peter
Krämer, Bernhard K.
Yard, Benito A.
Hauske, Sibylle J.
The CNDP1 (CTG)(5) Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration
title The CNDP1 (CTG)(5) Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration
title_full The CNDP1 (CTG)(5) Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration
title_fullStr The CNDP1 (CTG)(5) Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration
title_full_unstemmed The CNDP1 (CTG)(5) Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration
title_short The CNDP1 (CTG)(5) Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration
title_sort cndp1 (ctg)(5) polymorphism is associated with biopsy-proven diabetic nephropathy, time on hemodialysis, and diabetes duration
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434468/
https://www.ncbi.nlm.nih.gov/pubmed/28553654
http://dx.doi.org/10.1155/2017/9506730
work_keys_str_mv AT albrechtthomas thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT zhangshiqi thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT braunjanad thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT xiali thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT rodriquezangelica thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT qiujiedong thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT petersverena thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT schmittclausp thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT vandenbornjacob thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT bakkerstephanjl thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT lammertalexander thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT koppelhannes thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT schnuellepeter thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT kramerbernhardk thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT yardbenitoa thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT hauskesibyllej thecndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT albrechtthomas cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT zhangshiqi cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT braunjanad cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT xiali cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT rodriquezangelica cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT qiujiedong cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT petersverena cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT schmittclausp cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT vandenbornjacob cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT bakkerstephanjl cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT lammertalexander cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT koppelhannes cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT schnuellepeter cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT kramerbernhardk cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT yardbenitoa cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration
AT hauskesibyllej cndp1ctg5polymorphismisassociatedwithbiopsyprovendiabeticnephropathytimeonhemodialysisanddiabetesduration